糖皮质激素治疗重症药物性肝损伤的临床研究

摘要/Abstract

摘要： 目的探索糖皮质激素治疗重症药物性肝损伤的疗效和安全性。方法 37例重症药物性肝损伤患者分为激素治疗组16例和对照组21例。对照组采用常规保肝、退黄药物方案;激素组在对照组治疗基础上,加用小剂量、短疗程糖皮质激素治疗,观察生化学应答情况、有效率和安全性。结果激素治疗组生化学应答较早,ALT、AST、TBil、DBil、ALP水平在治疗2周时分别为(93.2±65.6) U/L;(61.7±30.7) U/L;(168.3±98.9) μmol/L;(124.7±81.4) μmol/L;(117.2±40.1) U/L、4周时分别为(52.6±32.0) U/L;(77.4±144.1) U/L;(88.9±59.7) μmol/L;(64.7±48.4) μmol/L;(116.6±63.1) U/L均较治疗前(172.9±104.8) U/L;(264.7±169.7) U/L;(259.1±108.8) μmol/L;(182.2±82.4) μmol/L;(153.8±69.9) U/L显著降低(P均<0.05);对照组治疗2周仅ALT、AST降低明显(P<0.05),而TBil、DBil于治疗4周后方明显降低(P均<0.05);两组GGT治疗前后均无显著改善(P>0.05)。治疗4周时激素组治疗有效率、显效率均显著高于对照组(93.8%比66.7%,χ²=11.919,P=0.001;87.5%比57.1%,χ²=6.081,P=0.014)。两组总体不良反应发生率差异无统计学意义(P>0.05)。结论早期应用小剂量、短疗程糖皮质激素,可有效地治疗重症药物性肝损伤,且安全性较好。

关键词: 药物性肝损伤, 胆汁淤积, 糖皮质激素

Abstract: Objective To investigate the efficacy and safety of glucocorticoid in treatment of severe drug-induced liver injury (DILI). Methods Thirty-seven patients with severe DILI were divided into control group (n=21) and glucocorticoid group (n=16), who received only conventional therapy and conventional therapy plus small dose of glucocorticoid in short course, respectively. Results In glucocorticoid group, levels of alanine aminotransferase (ALT), aspartate transaminase (AST), total bilirubin (TBil), direct bilirubin (DB) and alkaline phosphatase (ALP) were significantly decreased at week 2 (93.2±65.6; 61.7±30.7; 168.3±98.9; 124.7±81.4; 117.2±40.1) and week 4 (52.6±32.0; 77.4±144.1; 88.9±59.7; 64.7±48.4; 116.6±63.1) after treatment compared to those in baseline (172.9±104.8; 264.7±169.7; 259.1±108.8; 182.2±82.4; 153.8±69.9), respectively (P<0.05). In control group, ALT and AST levels were significantly lower at week 2 (P<0.05), and the serum levels of TB and DB decreased significantly at week 4 (P<0.05). The efficiency and effectiveness of treatment in glucocorticoid group were significantly higher than those in control group (93.8% vs 66.7%, χ²=11.919, P=0.001; 87.5% vs 57.1%, χ²=6.081, P=0.014). There was no significant difference in the incidence of adverse reactions between the two groups (P>0.05). Conclusion Early medication of small dose glucocorticoid with short course might be effective and safe for severe DILI.

Key words: Drug-induced liver injury, Cholestasis, Glucocorticoid

张玉果,赵素贤,李文聪,张庆山,杜慧娟,南月敏. 糖皮质激素治疗重症药物性肝损伤的临床研究[J]. 肝脏, 2017, 22(3): 214-218.

ZHANG Yu-guo, ZHAO Su-xian, LI Wen-cong, ZHANG Qing-shan, DU Hui-juan, NAN Yue-min. Treatment response of glucocorticoid in severe drug-induced liver injury[J]. Chinese Hepatolgy, 2017, 22(3): 214-218.

参考文献

[1] Chalasani NP, Hayashi PH, Bonkovsky HL, et al. ACG Clinical Guideline: the diagnosis and management of idiosyncratic drug-induced liver injury. Am J Gastroenterol, 2014, 109: 950-966.
[2] 中华医学会肝病学分会药物性肝病学组. 药物性肝损伤诊治指南. 肝脏, 2015, 20: 750-765.
[3] Danan G, Benichou C. Causality assessment of adverse reactions to drugs- I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries. J Clin Epidemiol, 1993, 46: 1323-1330.
[4] Bj rnsson ES. Epidemiology and risk factors for idiosyncratic drug-induced liver injury. Semin Liver Dis, 2014, 34:115-122.
[5] Li L, Jiang W, Wang J. Clinical analysis of 275 cases of acute drug-induced liver disease. Front Med China, 2007, 1: 58-61.
[6] 胡义扬, 黄甫. 中草药与药物性肝损伤. 中华肝脏病杂志, 2012, 20: 173-175.
[7] Van Pelt F N, Straub P, Manns MP. Molecular basis of drug-induced immunological liver injury. Semin Liver Dis, 1995, 15: 283-300.
[8] Kass GE. Mitochondrial involvement in drug-induced hepatic injury. Chem Biol Interact, 2006, 163: 145-159.
[9] 徐张巍, 许建明. 糖皮质激素治疗药物性肝损伤重症倾向的临床研究. 安徽医科大学学报, 2012, 47: 562-564.
[10] 苏婷婷, 张波, 周颜. 腺苷蛋氨酸联合糖皮质激素治疗药物性胆汁淤积性肝病的疗效. 胃肠病学和肝病学杂志, 2011, 20: 767-768.
[11] Hou FQ, Zeng Z, Wang GQ. Hospital admissions for drug-induced liver injury: clinical features, therapy, and outcomes. Cell Biochem Biophys, 2012, 64: 77-83.
[12] 李晶, 王鲁文,龚作烔. 糖皮质激素治疗重型肝炎有效性及安全性的Meta分析. 实用肝脏病杂志 2011, 12: 121-123.
[13] EASL Clinical Practice Guidelines: management of cholestatie liver diseases. J Hepatol, 2009, 51: 237-267.
[14] Wree A, Dechêne A, Herzer K, et al. Steroid and ursodesoxycholic Acid combination therapy in severe drug-induced liver injury. Digestion, 2011, 84: 54-59.
[15] Herishanu Y, Lishner M, Kitay-Cohen Y. The role of glucocorticoids in the treatment of fulminant hepatitis induced by dacarbazine. Anticancer Drugs, 2002, 13: 177-199.
[16] Zhang M, Zhou H, He R, et al. Steroids for the treatment of methimazole-induced severe cholestatic jaundice in a 74-year-old woman with type 2 diabetes. Endocrine, 2010, 37:241-243.